Abstract
Introduction: Association of Breast Surgery guidelines recommend that sentinel node biopsy (SNB) can safely be considered in patients following neoadjuvant chemotherapy (NAC), with accuracy of SNB improved by combining targeted axillary dissection (TAD) with SNB (TAD-SNB) in initially node positive patients. However, patient selection criteria for TAD-SNB are still to be optimised. Local policy in NHS Tayside from July 2016 was to offer TAD-SNB to patients with complete and excellent response on MRI breast and normal axillary ultrasound (AUSS) after NAC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
